Published in J Clin Invest on May 01, 1971
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10
High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med (2013) 0.90
PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release (2008) 0.87
Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Cancer (2015) 0.80
Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther (2015) 0.79
Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase. Vet Comp Oncol (2012) 0.78
Purification and properties of L-glutaminase-L-asparaginase from Pseudomonas acidovorans. J Bacteriol (1977) 0.78
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother (2016) 0.75
Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol (2017) 0.75
A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther (1959) 16.61
STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN. J Exp Med (1964) 6.30
Detection of non-precipitating antibodies in sera of individuals allergic to ragweed pollen by an in vitro method. J Exp Med (1958) 3.03
The immunoglobulin sequence. I. Arrest by 6-mercaptopurine and restitution by antibody, antigen or splenectomy. J Immunol (1965) 2.18
Inhibition of leukemias in man by L-asparaginase. Cancer Res (1967) 1.88
L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA (1967) 1.78
Studies on the mechanisms of hypersensitivity phenomena. XIV. Passive sensitization in vitro of human leukocytes to ragweed pollen antigen. J Immunol (1966) 1.75
Toxicity of E. coli L-asparaginase in man. Cancer (1970) 1.36
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer (1970) 1.31
Evaluation of L-asparagine metabolism in animals and man. Cancer Res (1970) 1.29
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29
The toxicity of Escherichia coli L-asparaginase. Cancer Res (1969) 1.25
Response to highly purified L-asparaginase during therapy of acute leukemia. Cancer Res (1969) 1.24
The antitumor activity of Escherichia coli L-asparaginase. Cancer Res (1966) 1.19
Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer (1966) 1.15
Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med (1969) 1.14
L-asparaginase. N Engl J Med (1970) 1.11
Escherichia coli L-asparaginase. Catalytic activity and subunit nature. Biochemistry (1970) 1.08
Demonstration of antibodies in the sera of grass-sensitive persons by the bisdiazotized-benzidine hemagglutination technique. J Allergy (1960) 1.07
IMMUNOLOGIC RESPONSIVENESS OF MAN TO PENICILLIN. JAMA (1963) 1.04
Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer (1970) 0.98
Purification and properties of asparaginase from escherichia coli B. Biochemistry (1969) 0.93
Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res (1969) 0.89
Serum sickness: serologic studies following prophylactic tetanus antitoxin. J Allergy (1960) 0.85
Neutralizing precipitin in the serum of a patient treated with L-asparaginase. J Lab Clin Med (1969) 0.81
[Attempt of treatment of acute lymphoblastic leukemia by L-asparaginase]. Presse Med (1969) 0.77
Antibodies in sera of allergic individuals. Mod Trends Immunol (1967) 0.77
Effects of L-asparaginase in acute myelocytic leukemia. JAMA (1969) 0.77
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
Field evaluation of Thayer-Martin medium for identification of meningococcus carriers. Am J Epidemiol (1965) 4.06
Immunofluorescence techniques for demonstrating bacterial pathogens associated with cerebrospinal meningitis. 3. Identification of meningococci from the nasopharynx of asymptomatic carriers. Am J Epidemiol (1966) 3.72
Isolation and amino acid sequence of cyclophilin. J Biol Chem (1986) 2.87
Preparation of lymphocyte-activating factor from continuous murine macrophage cell lines. Cell Immunol (1977) 2.81
Partial purification of human lymphocyte-activating factor (LAF) by ultrafiltration and electrophoretic techniques. J Immunol (1977) 2.58
Purification and properties of human lymphocyte activating factor (LAF). J Immunol (1977) 2.20
Inhibition of the synthesis of deoxyribonucleic acid in bacteria by 6-(p-hydroxyphenylazo)-2,4-dihydroxypyrimidine. I. Metabolic studies in Streptococcus fecalis. J Biol Chem (1966) 2.17
A rapid quantitative determination of deoxyribonucleoside triphosphates based on the enzymatic synthesis of DNA. Biochim Biophys Acta (1969) 1.91
Acetaminophen overdose: incidence, diagnosis, and management in 416 patients. Pediatrics (1978) 1.80
Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J Immunol (1986) 1.70
Activation of suppressor T cells by tumour cells and specific antibody. Nature (1974) 1.67
Leukocyte chemotactic activity of cyclophilin. J Biol Chem (1992) 1.63
Evidence that down-regulation of beta-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci U S A (1990) 1.51
Potentiation of the T lymphocyte response to mitogens. III. Properties of the mediator(s) from adherent cells. Cell Immunol (1974) 1.49
The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor. J Biol Chem (1995) 1.48
On the mode of action of BCG. Nat New Biol (1973) 1.47
Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci (1989) 1.44
Tamoxifen induces Na+ -dependent uridine transport and dome formation in a human breast tumor cell line. Cancer J Sci Am (2006) 1.42
A general journal in a specialized world. Yale J Biol Med (1976) 1.39
N-acetylcysteine causes false-positive ketone results with urinary dipsticks. Clin Chem (1990) 1.39
Activation of lymphoid cells by BCG in vitro. Cell Immunol (1975) 1.38
Cyclophilin-40, a protein with homology to the P59 component of the steroid receptor complex. Cloning of the cDNA and further characterization. J Biol Chem (1993) 1.37
Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis (2000) 1.34
L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol (1970) 1.31
Evaluation of L-asparagine metabolism in animals and man. Cancer Res (1970) 1.29
Atypical decubital fibroplasia. A distinctive fibroblastic pseudotumor occurring in debilitated patients. Am J Surg Pathol (1992) 1.25
Pulmonary manifestations in Behçet syndrome. Case report and review of the literature. Arch Intern Med (1976) 1.23
L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med (1971) 1.21
The N-terminal ATPase site in the large terminase protein gp17 is critically required for DNA packaging in bacteriophage T4. J Mol Biol (2001) 1.20
Cyclophilin, a primary molecular target for cyclosporine. Structural and functional implications. Transplantation (1988) 1.19
Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Biochem Biophys Res Commun (1996) 1.19
Isolation and characterization of a 40-kDa cyclophilin-related protein. J Biol Chem (1992) 1.17
Pharmacology of furosemide in the premature newborn infant. J Pediatr (1980) 1.16
Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med (1969) 1.14
Myelin embedded in polymerized glutaraldehyde-urea. J Ultrastruct Res (1972) 1.14
Antigen-antibody complexes generate Lyt 1 inducers of suppressor cells. J Immunol (1980) 1.11
Escherichia coli L-asparaginase. Catalytic activity and subunit nature. Biochemistry (1970) 1.08
Structure of peptide from active site region of Escherichia coli L-asparaginase. J Biol Chem (1977) 1.07
Age as a variable in acetaminophen overdose. Arch Intern Med (1981) 1.07
Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res (1986) 1.07
Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A (1978) 1.06
Uptake and nature of the intracellular binding of cyclosporin A in a murine thymoma cell line, BW5147. J Immunol (1984) 1.05
Novel single-pass exchange of circulating uridine in rat liver. Science (1981) 1.05
Concentrative uridine transport by murine splenocytes: kinetics, substrate specificity, and sodium dependency. Cancer Res (1987) 1.05
Morphological localization of PNS myelin proteins. Brain Res (1978) 1.04
Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. J Biol Chem (1993) 1.04
1H NMR studies on bovine cyclophilin: preliminary structural characterization of this specific cyclosporin A binding protein. Biochemistry (1986) 1.03
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer (1998) 1.01
Induction of the differentiation of HL-60 cells by phorbol 12-myristate 13-acetate activates a Na(+)-dependent uridine-transport system. Involvement of protein kinase C. Biochem J (1991) 1.01
Isolation, cDNA sequences, and biochemical characterization of the major cyclosporin-binding proteins of Toxoplasma gondii. J Biol Chem (1994) 1.00
Sympathetic innervation of murine thymus and spleen: evidence for a functional link between the nervous and immune systems. Brain Res Bull (1981) 1.00
Improved therapeutic index of methotrexate with "leucovorin rescue". Cancer Res (1973) 0.99
Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res (1984) 0.99
Methemoglobinemia resulting from absorption of nitrates. JAMA (1979) 0.98
Immunosuppressive therapy for the eye changes of Graves' disease. J Clin Endocrinol Metab (1970) 0.97
Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol (1997) 0.97
Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: a possible role for different heat shock protein-binding immunophilins in glucocorticosteroid receptor-mediated gene expression. Proc Natl Acad Sci U S A (1995) 0.97
D-penicillamine therapy of acute arsenic poisoning. J Pediatr (1977) 0.97
Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res (1998) 0.96
Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients. Anesthesiology (1988) 0.96
Characteristics of children presenting with chest pain to a pediatric emergency department. CMAJ (1990) 0.95
Polymerizable glutaraldehyde-urea mixtures as polar, water-containing embedding media. J Ultrastruct Res (1972) 0.95
Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res (1981) 0.95
Cyclophilin-40: evidence for a dimeric complex with hsp90. Biochem J (1995) 0.95
Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications. Biomedicine (1976) 0.95
Panel discussion. Management of acetaminophen overdose. Arch Intern Med (1981) 0.94
Case report: clinical findings and successful resection of melanoma metastatic to the right atrium. Cancer Invest (1994) 0.94
Control of the formation of uridine diphospho-N-acetyl-hexosamine and glycoprotein synthesis in rat liver. J Biol Chem (1966) 0.93
Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa). Am J Physiol (1991) 0.93
Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. Cancer Res (1968) 0.93
Structural evidence for distinct IgG subclass-specific Fc receptors on mouse peritoneal macrophages. J Exp Med (1980) 0.92
Comparison of the metabolic and toxic effects of 2-chloropropionate and dichloroacetate. J Pharmacol Exp Ther (1982) 0.92
Production of L-asparagine by tumor cells and the effect of asparagine analogs. Biochem Pharmacol (1972) 0.92
Structural elements pertinent to the interaction of cyclosporin A with its specific receptor protein, cyclophilin. Biochem Pharmacol (1990) 0.91
Calmodulin, cyclophilin, and cyclosporin A. Science (1986) 0.91
Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro. Cancer Res (1979) 0.91
Effects of surgically induced instability on rat knee articular cartilage. J Anat (1982) 0.91
The production of tolerance to human erythrocytes in the rat with cytosine arabinoside or cyclophosphamide. J Immunol (1969) 0.90
5-Diazo-4-oxo-L-norvaline: reactive asparagine analog with biological specificity. Science (1968) 0.90
Suppressor T cells induced by soluble immune complexes can adoptively transfer inhibition of cytophilic antibody receptors on macrophages. Cell Immunol (1979) 0.90
Metabolism of phospholipids in peripheral nerve from rats with chronic streptozotocin-induced diabetes: increased turnover of phosphatidylinositol-4,5-bisphosphate. J Neurochem (1982) 0.90
Effects of chemotherapeutic agents on the immune response. I. Cancer Invest (1984) 0.90
1H NMR studies on bovine cyclophilin: preliminary structural characterization of its complex with cyclosporin A. Biochemistry (1990) 0.90
Effect of activated charcoal administration on acetylcysteine serum levels in humans. Am J Hosp Pharm (1981) 0.90
Glycogen accumulation in tibial nerves of experimentally diabetic and aging control rats. J Neurol Sci (1982) 0.90
Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother (1991) 0.90
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res (1985) 0.89
Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood (1986) 0.89
Clinical, biological, and biochemical effect of pyrazofurin. Cancer Res (1978) 0.89
Control of purine biosynthesis de novo by orotic acid in vivo and in vitro. Biochim Biophys Acta (1968) 0.89
Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol (1995) 0.89
Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Cancer Res (1979) 0.89
Vascularization and basement membranes of the chick brain in light microscopy. Anat Rec (1968) 0.89
Acute carbamazepine toxicity resulting from overdose. Neurology (1981) 0.88
Salicylate toxicity following therapeutic doses in young children. Clin Toxicol (1981) 0.88
Toxoplasma gondii tachyzoites possess an unusual plasma membrane adenosine transporter. Mol Biochem Parasitol (1995) 0.88